Pacific Biosciences of California Cash and ST Investments:
112.30M for Dec. 31, 2012Pacific Biosciences of California Historical Cash and ST Investments Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 112.30M |
| Dec. 31, 2012 | 100.58M |
| Sept. 30, 2012 | 119.40M |
| June 30, 2012 | 137.11M |
| March 31, 2012 | 161.35M |
| Dec. 31, 2011 | 177.43M |
| Sept. 30, 2011 | 193.70M |
| June 30, 2011 | 216.59M |
| March 31, 2011 | 248.55M |
| Dec. 31, 2010 | 283.67M |
| Sept. 30, 2010 | 112.93M |
| June 30, 2010 | 138.76M |
| Dec. 31, 2009 | 92.74M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and short term investments are considered very liquid assets. For instance, if a company needs immediate liquidity, cash and short term investments can be be quickly used. Cash and short term investments are frequently used in liquidity ratios.
Learn More
PACB Cash and ST Investments Benchmarks
| Companies | |
|---|---|
| NPS Pharmaceuticals | 100.72M |
| Lexicon Pharmaceuticals | 223.21M |
| MannKind Corporation | 61.84M |
PACB Cash and ST Investments Rankings
| Overall |
77th percentile 1713 of 7593 |
| Sector |
73rd percentile 171 of 650 in Healthcare |
| Industry |
75th percentile 58 of 237 in Biotechnology |
PACB Cash and ST Investments Range, Past 5 Years
| Minimum | 92.73M | Dec 2009 |
| Maximum | 283.67M | Dec 2010 |
| Average | 161.16M |
